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Introduction
Glucocorticoids are adrenocortical hormones
contributing fundamentally to the maintenance of
basal and stress-related homeostasis in all higher
organisms. They influence the activity of almost every
cell in the body, modulate the expression of appro -
ximately 10% of human genes and are essential for
growth, development and differentiation. Conse -
 quently, these hormones are implicated in the patho -
genesis of a number of diseases and, because of their
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Kratak sadr`aj: Glukokortikoidni hormoni su neophodni
za odr`avanje homeostaze, imaju klju~nu ulogu u terapiji
inflamatornih i autoimunih poreme}aja i u~estvuju u pato -
genezi mnogih bolesti. Ovi hormoni deluju posredstvom
unutar}elijskog receptornog proteina, glukokortikoidnog
receptora, koji funkcioni{e kao inducibilan transkripcioni
faktor aktiviran ligandom. Mnogi sintetski glukokortikoidi
koriste se kao efikasni antiinflamatorni i imunosupresivni
agensi, ali je njihov terapeutski u~inak ograni~en {irokim
spektrom i intenzitetom sporednih efekata. Jedan od najva -
` nijih ciljeva farmaceutske industrije jeste sinteza steroidnih
i nesteroidnih liganada GR-a sa izra`enom terapeutskom
efika sno{}u i redukovanim ne`eljenim efektima. Terape -
utski u~inak glukokortikoidnih agonista ~esto je umanjen
zbog rezistencije na glukokortikoide koja zavisi od: do stup -
nosti ciljnih }elija hormonima, metabolizma steroida, nivoa
ekspresije i izoformskog sastava GR, mutacija i poli -
morfizama u genu za receptor i interakcije receptora sa
{aperonima. O~ekuje se da veliki prodor u upoznavanju
klju~ne uloge glukokortikoidnih hormona u odr`avanju ho -
meostaze i patogenezi bolesti, kao i u rasvetljavanju mole -
ku larnih mehanizama terapeut skih efekata antiinfla ma tor -
nih lekova koji deluju posred stvom GR rezultira iz napretka
savremenih tehnologija za globalno izu~avanje ekspresije
gena i bioinformatike.
Klju~ne re~i: glukokortikoidni hormoni, glukokortikoidni
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Summary: Glucocorticoid hormones are essential for life,
have a vital place in the treatment of inflammatory and
autoimmune diseases and are increasingly implicated in
the pathogenesis of a number of common disorders. Their
action is mediated by an intracellular receptor protein, the
glucocorticoid receptor (GR), functioning as a ligand-indu -
cible transcription factor. Multiple synthetic glucocorticoids
are used as potent antiinflammatory and immuno sup -
pressive agents, but their therapeutic usefulness is limited
by a wide range and severity of side-effects. One of the
most important pharmaceutical goals has been to design
steroidal and non-steroidal GR ligands with profound
therapeutic efficacy and reduced unwanted effects. The
therapeutic benefit of glucocorticoid agonists is frequently
compromised by resistance to glucocorticoids, which may
depend on: access of the hormones to target cells, steroid
metabolism, expression level and isoform composition of
the GR protein, mutations and polymorphisms in the GR
gene and association of the receptor with chaperone pro -
teins. The major breakthrough into the critical role of
glucocorticoid signaling in the maintenance of homeostasis
and pathogenesis of diseases, as well as into the molecular
mechanisms underlying the therapeutic usefulness of
antiinflammatory drugs acting through the GR is expected
to result from the current progress in large-scale gene
expres sion profiling technologies and computational
biology.
Keywords: glucocorticoid hormones, glucocorticoid
receptor, mechanism of action, pathogenesis of disease,
antiinflammatory drugs
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antiinflammatory and immunosuppressive actions,
are widely used in the therapy. However, when given
therapeutically they produce many adverse side-
effects. For decades, many researchers focused their
efforts on these hormones, attempting to design
synthetic analogues with maximal therapeutic efficacy
and reduced undesired effects.
Glucocorticoid actions are mediated by an intra -
cellular receptor protein, the glucocorticoid receptor
(GR). GR is a member of the superfamily of nuclear
receptors, which function as ligand-inducible trans -
cription factors. Unlike other receptors of this
superfamily, unliganded GR is predominantly loca -
lized within the cytoplasm of target cells, but after
hormone binding it rapidly translocates to the nu -
cleus. The GR is a multifunctional protein consis ting
of several functional domains. It interacts with many
other signaling proteins, which in addition to the
receptor itself, represent potential drug targets for the
manipulation of cellular responses to glucocor ticoids.
The numerous actions of glucocorticoids are
mediated by a number of GR isoforms capable of
forming homo- and hetero-dimers. Multiple GR mo no -
mers and dimers expressed at different levels in a cell-
specific manner exert quantitatively and quali tatively
different transcriptional activities, making the gluco -
corticoid signaling system highly versatile.
It is of utmost clinical importance to elucidate
the molecular mechanisms by which glucocorticoids
and their synthetic analogues produce their complex
and varied actions, because they are used in the
treatment of inflammatory and autoimmune disor -
ders, such as asthma, rheumatoid arthritis, inflamma -
tory bowel disease, and also as immunosuppresive
therapy after organ transplantation. The additional
reason for studying the molecular mechanisms of
glucocorticoid action lies in the fact that dere gu lation
of the secre tion and/or activity of endogenous
glucocorticoids is implicated in the pathogenesis of a
number of com mon disorders that pose a growing
clinical burden, including obesity, type 2 diabetes, the
metabolic syndrome, essential hypertension, athero -
sclerosis with its cardiovascular sequelae, osteo po -
rosis and stress-related psychiatric disorders, such as
anxiety, depression, posttraumatic stress disorder,
insomnia, and chronic pain and fatigue syndromes.
Glucocorticoid hormones
Physiological effects
The principal endogenous glucocorticoids are
cortisol and corticosterone, cortisol being the pre -
dominant glucocorticoid in man. Glucocorticoids
exert widespread actions essential for the mainte -
nance of homeostasis and enable the organism to
prepare for, respond to and cope with physical and
emotional stress (1). Their influence on metabolism
encompasses stimulation of carbohydrate and protein
breakdown, as well as complex effects on lipid depo -
sition and breakdown. They are also important regu -
lators of immune and inflammatory processes and are
required for host defense. Stress-protective actions of
these hormones are now considered to be based on
their antiinflammatory and immuno suppressive
activity, since they quench the pathophysiological res -
pon ses to tissue injury and inflammation preventing
them from overshooting and threatening the ho meo -
stasis themselves (2). A wide spectrum of physiolo -
gical actions of the endogenous glucocorti coids also
includes their effects on blood pressure, bone, cell
growth and apoptosis. Within the central nervous
system (CNS), glucocorticoids target both neurons
and glial cells, and are equally important during
development, when they play an organizational role
in the brain, and in the adulthood, when they
contribute to neuronal plasticity. Other central effects
of glucocorticoids include complex changes in mood,
arousal, cognition, sleep, behavior, modulation of
food intake, body temperature, pain perception and
neuroendocrine function (3). 
Persistent and pronoun ced elevations in
circulating glucocorticoids, due to hypersecretion of
endogenous hormones, like in Cushing’s syn -
drome/disease, or to prolonged admi nistration of
exoge nous steroids, frequently cause amplification of
their metabolic and physio logical effects and lead to
a variety of pathological states. Likewise, insufficient
glucocorticoid secretion, which may arise from
Addison’s disease, the adrenogenital syndrome or
pituitary disease, is also accompanied by pathologies,
but with the opposite characteristics (3, 4). 
Secretion 
The release of glu cocorticoids from the zona
fasciculata of the adrenal cortex into the systemic
circulation is pulsatile, with the pulse amplitude
following a circadian rhythm. The circa dian and
stress-induced secretion of the glucocor ticoids is
gover ned by the hypothalamic-pituitary-adreno -
cortical (HPA) axis. The hypothala mus, as a sensor of
changes in the external and internal environment,
receives and integrates neural and hu moral infor -
mation from many sources. Two hypotha lamic
neurohormones, corticotrophin-releasing hormone
(CRH) and arginine vasopressin (AVP), reach the
anterior pituitary gland via the hypophy seal–portal
blood vessels, and act through specific receptors to
trigger the release of the adrenocor ticotrophic
hormone (ACTH) into the systemic circu lation.
ACTH, in turn, acts on the adrenal cortex via type 2
melanocortin receptors to initiate the synthesis and
release of cortisol. The sensitivity of the HPA axis to
incoming stimuli is modulated by a negative feed back
mechanism, in which the sequential release of
CRH/AVP and ACTH is suppressed by endogenous
glucocorticoids (5). 
Antiinflammatory and immuno su ppre ssive
actions 
Corti costeroids are the most effective anti-
inflam ma tory therapy for many chronic inflammatory
diseases, such as asthma, rheumatoid arthritis and
inflam matory bowel disease, but are relatively ineffe c -
tive in other diseases, such as chronic obstructive
pulmonary disease (COPD). Chronic inflam mation
involves the infiltration and activation of many inflam -
matory and immune cells, which release inflam -
matory mediators that interact and activate structural
cells at the site of inflammation. Different inflam -
matory diseases involve different cells and mediators
(6), but common to all of them is increased
expression of multiple inflam matory proteins, which
are regulated at the level of gene transcription by
proinflammatory transcription factors, such as nuclear
factor-kB (NF-kB) and activating protein-1 (AP-1). It is
now believed that chromatin remodeling plays a
critical role in the transcriptional control of inflam -
matory genes. Stimuli that switch these genes on act
by changing the chromatin structure of the genes,
whereas corticosteroids reverse this process mainly by
the binding of liganded GR to coactivators and
recruit ment of histone deacetylase-2 (HDAC2) to the




Similar to other steroid hormone receptors, GR
is a modular protein organized into three major struc -
tural/functional domains: a ligand binding domain
(LBD) at the C-terminus, a DNA-binding domain
(DBD) in the central part of the protein and an N-
terminal regulatory domain harboring a strong
transcriptional activation function AF-1 (8). Recently,
the crystal structure of the LBD of the human GRa
was resolved (9, 10). The LBD is composed of a-
helices and b-strands folded into a three-layer helical
sandwich and forming a hydrophobic steroid binding
pocket. In addition to the steroid binding pocket the
LBD also harbors a secondary, ligand-dependent
trans-activation function AF-2 (11). Upon ligand
binding, the LBD undergoes a conformational
change that results in the »closing« of the pocket by
helix 12. The interaction between co-activators and
GR is very sensitive to the structure of the ligand that
is bound in the pocket. Thus, agonist binding to the
LBD induces the reorientation of a critical Q-helix and
the formation of a binding pocket for a family of co-
activator proteins that play essential roles in
transactivation (12, 13).
The DBD contains two Zn-fingers one of which
is required for the specific recognition of the response
element in the major groove of the DNA helix (14),
while the other is involved in the dimerization of the
receptor occurring upon its interaction with the DNA
response element.
The N-terminal domain of the GR contains the
glucocorticoid-independent AF1 transactivation
subdomain. This region has been shown to interact
with the TFIID complex and TBP of the general
transcription machinery (15).
Signaling cascade of the 
glucocorticoid receptor
Nuclear translocation
GR is expressed in many cell types at a density
of 2000 to 30,000 molecules per cell (16). In the
unliganded state it is located in the cytoplasm within
a multiprotein chaperone complex, the key
component of which is a heat shock protein Hsp90,
which maintains the receptor in an inactive state
poised to bind its ligand. Apart from Hsp90 this
complex contains the heat shock proteins Hsp40 and
Hsp70, and other proteins, such as p23 and p60
(17). It is postulated that Hsp70 initiates the opening
of the hydrophobic steroid-binding pocket in an ATP-
dependent manner, enabling association of Hsp90
with the LBD of the receptor, which is a prerequisite
for keeping the receptor in a ligand-receptive state
(18).
The receptor is a phosphoprotein that becomes
hyper-phosphorylated upon ligand binding. In the
absence of the hormone, GR is predominantly phos -
phorylated at Ser203, and addition of the hormone
increases phosphorylation at both Ser203 and
Ser211 (19). Phosphorylation at Ser211 coincides
with increased trans-activation properties of GR,
possibly reflecting a conformational change that
modulates the interaction with co-activators (19, 20).
Phosphorylation status of the GR influences its intra -
cellular localization: when phosphorylated at Ser203,
the receptor localizes predominantly to the cyto -
plasm, whereas phosphorylation at Ser211 causes
partition between the cytoplasmic and the nuclear
compartment. When leaving the nuclear compart -
ment, GR becomes dephosphorylated at Ser211 and
can either be recycled by recruitment in a chaperone
complex, which facilitates Ser203 phosphorylation, or
is degraded (21).
Interaction with DNA regulatory elements
In the nucleus, activated GR can interact with
the regulatory regions of responsive genes to alter the
level of gene expression. GR can activate gene
transcription by direct binding to the so-called simple
glucocorticoid-responsive elements (GREs). A con -
sen sus GRE is the pentadecameric imperfect palin -
drome GGTACAnnnTGTTCT (22) with the 3’ half
conserved, and the 5’ half highly variable. A GR
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monomer first binds to the 3’ half-site, after which the
5’ half-site is occupied by a second monomer to form
a DNA-bound dimer (23). The 3-basepair spacer
between the half-sites is a strict requirement for
cooperative binding of the two GR monomers to the
palindromic GRE (24).
The response of many genes to glucocorticoids
depends not only on GR binding to the GRE, but
additionally requires the binding of other transcription
factors to adjacent binding sites. Since these response
elements are both spatially and functionally clustered,
they are referred to as glucocorticoid responsive units
(GRUs) (25). Therefore, GRUs act by integrating
multiple signal inputs into one response. Different
GRUs diverge widely in the identity of the bound
transcription factors, and in the order and number of
response elements in each unit. Thus, a tissue-specific
response to a glucocorticoid is likely to result from the
composition of its regulatory regions allowing for
specific combinations of the GR with tissue specific
accessory factors. GREs that negatively influence the
trans cription of responsive genes are referred to as
negative GREs (nGREs). In this mode of regulation,
direct binding of GR to the nGRE is required. A nGRE
has a similar recognition sequence as a GRE, altho ugh
the consensus sequence of a nGRE is more va riable
(ATYACnnTnTGATCn) than that of a GRE (26).
In certain genes, GR does not bind directly to
the DNA to exert its effect, but is recruited to DNA-
bound transcription factors in a regulatory complex, a
mechanism known as tethering. In these cases the
receptor seems to behave as a ligand-inducible co-
regulator that employs protein-protein interactions to
exert its effect, which, interestingly, can be both
positive and negative (8).
Activation of transcription
The N-terminal domain of GR can interact with
the general transcription factor TFIID (15), providing
a mechanism by which the receptor can directly
influence the rate of transcription. In addition, several
transcription co-factors, which can associate with the
DNA-bound receptor, can act as protein bridges with
the transcription machinery to regulate gene expres -
sion (13). Thus, co-activators of the p160 family of
transcription factors (SRC1, TIF-2/GRIP1, pCIP)
interact with ligand-bound receptors (27) and recruit
secondary co-activators essential for activation,
including CBP/p300 (28, 29). Some of these possess
histone acethyltransferase (HAT) activity required for
chromatin remodeling and subsequent access of the
transcriptional machinery to promoters (29, 30).
How ever, some of these co-activators can also
interact with the basal transcription machinery and
activate the transcription of target genes (31).
Repression of transcription
Repression of transcription by GR is mostly
achieved by antagonizing the trans-activating pro -
perties of other transcription factors via different regu -
latory mechanisms. First, the receptor can intrinsically
inhibit gene expression by the direct binding to nGRE
sequences. More complex mecha nisms involve the
receptor interaction with other transcrip tion factors.
Antiinflammatory actions of glucocor ticoids are typ -
ically mediated by proinflammatory transcription
factors, such as NF-kB and AP-1 (32). Several models
exist to explain the glucocorticoid-in duced repression
of AP-1 and NF-kB signaling. In the direct-interaction
model, GR and AP-1 interact and prevent the binding
of each other to their response elements (33). In the
competition model, GR and AP-1 compete with one
another for binding to their overlapping response
elements, while in the co-activator competition
model, GR competes with NF-kB and/or AP-1 for
binding to CBP, which is present in the cell in limiting
amounts (28, 34). Furthermore, the GR-mediated
repression of trans-activation by the p65 subunit of
NF-kB is increased in the presence of CBP, suggesting
that CBP functions as an integrator of the NF-kB/GR
cross-talk (35). In the HAT inhibition model, GR
binding to CBP inhibits recruitment of CBP by DNA-
bound p65, reducing the HAT activity of the complex
(32). Yet another possibility is an up-regulation of the
inhibitor of NF-kB action (I-kB) in response to gluco -
corticoids (36). However, recent results showing that
dimerization-impaired GR DNA-binding domain is
capable of DNA-binding (37) and up-regulation of
GRE-dependent genes (38) have shed some doubts
on whether the antiinflammatory actions of gluco -
corti coids are indeed independent of DNA-binding.
Glucocorticoid receptor as a
pharmacological target 
The structure of the GR LBD has recently been
solved (9) and it has been shown that the ligands with
only slightly different structure can considerably alter
the final conformation of the ligand–receptor
complex, and thus influence the recruitment of
various transcription co-factors and the biological
function of the receptor. The molecular insights into
the structure of the GR LBD provided important clues
for a better understanding of the glucocorticoid
signaling and for designing safer and more efficient
medi cations. Namely, they led to concerted efforts by
the pharmaceutical companies to develop selective
GR ligands with preserved beneficial antiinflam -
matory activity, but reduced pleiotropic side-effect
profile, which includes adversities such as fat redi -
stribution, hyperglycemia, obesity, skin atrophy and
osteoporosis (39). The tested compounds derive from
different sources, such as from high throughput
screening, where hundreds of thousands of compounds
are randomly screened, or from rational drug design,
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beginning with targeted modifications of the known
GR-ligands. A screen for the ligands with a the ra peu -
tically beneficial profile usually consists of receptor
binding assays and cellular in vitro tests for GR-
mediated transactivation and transrepression, fol -
lowed by in vivo analyses of their effects in various
animal models of inflammation (40–42). At present
various synthetic GR ligands with specific pharmaco -
kinetic and pharmacodynamic properties are avai -
lable for therapeutic use. Some of these novel
compounds are highlighted in this section.
Long circulating liposomal glucocorticoids
One of the approaches to develop novel glu co -
corticoids or glucocorticoid-substituting com pounds
with an improved effect/side-effect ratio was the
optimization of formulation for a systemic treat ment
with targeted release of the drug. The efforts toward
that end led to the use of liposome-encap sulated
steroids for the treatment of rheumatoid arthritis. One
example is the encapsulation of pred nisolone or
dexamethasone in liposomes, an appro ach that
enabled prolonged and more targeted availability of
the drug in comparison with the drugs applied
without liposomes (43). This administration route
proved to be especially useful in rheumatoid arthritis
and atherosclerosis, since liposomes display high
affinity for macrophages in inflamed tissues, and
these cells do not serve only as targets, but also play
a crucial role in the release of glucocorticoids from
liposomes and the generation of their relatively high
and prolonged concentration in the synovium.
Nitro-steroids
A second approach to improve the ratio of
desired and undesired effects was to create nitro-
steroids by combining known steroidal GR-ligands
with nitric oxide (NO). Nitroxy derivatives of the ste -
roid scaffold slowly release NO, displaying enhanced
antiinflammatory activity without increasing the dose
of the steroid (44). Two interesting substances are
NO-prednisolone (NCX-1015), which exerts 10-fold
stronger antiinflammatory effects than conventional
pred nisolone, and NO-hydrocortisone (NCX-1004).
At the same time, these drugs induce fewer side-effects,
especially on the bones (44, 45). A possible expla -
nation for the strong antiinflammatory activity of
nitro-steroids may lie in the post-translational modifi -
cation of GR through tyrosine nitration (44).
Selective glucocorticoid receptor agonists
Major efforts have been made and promising
preclinical results achieved in the search for GR
ligands that trigger molecular mechanisms of the GR
action very selectively, so as to completely dissociate
transactivation from transrepression by the receptor,
with the goal of reducing the risk for side-effects,
which are mainly based on transactivation, while
maintaining the antiinflammatory efficacy, which
relies on transrepression. These drugs, the so-called
dis so c iating ligands or selective GR agonists
(SEGRA), induce a conformational change of the
receptor favoring GR/protein interactions, while
disfavoring the receptor binding to DNA (39, 46).
In the last years, an increasing number of
SEGRAs has been described. Very interesting
substances are A276575 and its four enantiomeres
(47). They all show equal affinity for the GR as
dexamethasone, but posses less than 5% of its
transactivation ability. Another potentially useful
SEGRA is the substance ZK216348 with potent anti-
inflammatory activity, but with a 60-fold weaker
transactivation capacity compared to prednisolone,
and even 300-fold weaker compared to dexametha -
sone (48). Haegeman’s group described the first
example of a dissociating compound, compound A,
isolated from natural sources. It binds to the GR with
an affinity similar to that of dexamethasone and
selectively triggers transrepression. It seems to be as
efficient an antiinflammatory agent as dexametha -
sone, and moreover, induces no increase in the blood
glucose level (49).
The dissociating substances can be expected to
be introduced into clinical medicine in the nearby
future, but more in vivo studies are obviously needed
to define their benefit/risk ratio in humans, since their
performance in animals does not necessarily ensure
efficacy in the complex situation of human disease.
Secondly, the effects of SEGRAs observed at the
cellular level in vitro may differ from those that occur
on various cell types in vivo. Finally, the transacti -
vation/transrepression model for the screening of
anti-inflammatory glucocorticoids with reduced side-
effects, although attractive, has some limitations.
These mostly stem from the fact that there are genes
that negatively regulate the processes in the immune
system, but are transcriptionally upregulated by the
GR (50, 51). Thus, SEGRAs acting exclusively via
transrepression may not reach the overall immuno -
sup pressive potential of conventional glucocorticoids.
Likewise, the mechanisms underlying the occurrence
of undesired effects are complex and subtle. For
many of the metabolic effects transactivation seems
to be the most prominent mechanism, as shown for
genes encoding the enzymes of gluconeogenesis and
protein catabolism (52). However, the mechanisms
underpinning the induction of osteoporosis and skin
atrophy are not very well understood and the disso -
ciation between transactivation and transrepression
does not promise to be a good enough indicator of
the compound’s therapeutic usefulness (46).
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Physiological and pathological 
variations in tissue responsiveness 
to glucocorticoids
Glucocorticoids are necessary for life and are
essential in all aspects of health and disease as they
regulate vital processes from mitosis to apoptosis,
from metabolism to growth and development. How -
ever, responses to glucocorticoids vary among indi -
viduals, cells and tissues. These hormones are used to
treat a wide variety of allergic and inflam matory
diseases, but owing to their ability to regulate the
expression of genes involved in cell cycle prog ression
and apoptosis, they are also effective in the treatment
of lymphoproliferative diseases, such as leukemia and
Hodgkin’s disease, with particularly beneficial results
being obtained in childhood acute lymphoblastic
leukemia (ALL). Besides, they are applied as an
indispensable part of the immunosu ppre ssive regimes
to prevent organ transplant rejection (39).
Unfortunately, in about 30% of the patients the
response to glucocorticoids is poor, but since the
glucocorticoid resistance in most cases is tissue
specific, the unresponsive patients still suffer from
numerous side-effects. As insensitivity to glucocor -
ticoids limits the therapeutic benefit of glucocorticoid
agonists and is usually positively correlated with poor
prognosis in proliferative disorders (53, 54), it is of
utmost clinical importance to elucidate the underlying
molecular mechanisms. Within this context the
following factors determining tissue responsiveness to
glucocorticoid hormones are considered herein:
mechanisms regulating the access of glucocorticoids
to target cells, metabolism of the glucocorticoid
hormones, expression level and isoform composition
of the GR protein, mutations and polymorphisms in
the GR gene, and association of the receptor with
chaperone proteins.
Access of glucocorticoids to target cells
Approximately 95% of cortisol in the circulation
is bound to a carrier protein, corticosteroid-binding
globulin (CBG), while only the free steroid has ready
access to target cells. The ability of glucocorticoids in
the systemic circulation to reach target cells can be
compromised by transporter proteins, called multi -
drug-resistant P-glycoproteins, which are expressed in
a tissue-specific manner and act by actively pumping
steroids out of the cells. They, thus, provide a mecha -
nism for the tissue- and steroid-specific delivery of
glucocorticoids to target cells, contributing to subtle
differences in the pharmacological profile of various
compounds and their deregulation may lead to the
development of glucocorticoid resistance. Particular
interest has been focused on the expression of these
proteins in the blood–brain barrier, where they limit
the access of steroids such as dexamethasone and, to
a lesser extent, cortisol and corticosterone, to the
brain (55).
Pre-receptor metabolism of glucocorticoids
Probably the most important factor regulating
the access of endogenous glucocorticoids to their
receptors is the metabolism of steroids within the
target cells by 11b-hydroxysteroid dehydrogenase
(11b-HSD) enzymes, a phenomenon known as pre-
receptor metabolism. In human tissues, these
enzymes catalyze the interconversion of cortisol and
its inactive metabolite, cortisone. Two distinct
isoforms of 11b-HSD have been cloned and
characterized: type 1 (11b-HSD1) and type 2 (11b-
HSD2) (56). 11b-HSD2 is an NAD+-dependent,
constitutive enzyme that acts exclusively as a dehy d -
rogenase and is colocalized with the mineralo -
corticoid receptor (MR) in tissues such as the kidney,
parotid gland, sweat glands, colon and vascular
smooth muscle cells. Patients with specific mutations
in the 11b-HSD2 gene develop severe corticosterone-
dependent hypertension and other features of
apparent mineralocorticoid excess (56). The other
isoform, 11b-HSD1, is expressed mainly in the liver,
adipose tissue and brain, but is also found in other
tissues, and is subject to regulation by a variety of
factors including glucocorticoids, stress, sex steroids
and cytokines. In vivo it functions solely as a re duc -
tase regenerating biologically active cortisol from inert
steroids, cortisone or 11-dehydrocor ticosterone (57).
As 11b-HSD1 is found mainly in tissues in which the
high affinity MR is sparse, whereas the low-affinity GR
is abundant, it is thought that its principal role is to
amplify the local concentration of active glucoco r -
ticoids in the tissues, such as the liver, in which the
steroids have a key regulatory role. Several lines of
evidence, including observations that 11b-HSD1
blockade promotes insulin secretion, support the view
that 11b-HSD1 is an important factor in the
development of insulin resistance, obesity and other
metabolic disturbances. Consequently, drugs that
selectively block 11b-HSD1 are now considered a
promising pharmacological target.
Glucocorticoid receptor expression
In many cases, the level of GR expression is
closely correlated with the magnitude of the glu co -
corticoid response (58). The cellular level of GR is
dynamic and regulated in a cell-type specific manner
by the surrounding concentration of the ligand (59).
Administration of GR agonists results in down-
regulation of the GR (60, 61) by the mechanisms that
can be attributed to reduced transcription of the GR
gene, as well as to decreased stability of the GR
mRNA and protein (62). In contrast, hormone-in -
duced upregulation of GR (autoinduction) is
associated with glucocorticoid sensitivity. For
example, T-cells that exhibit GR autoinduction at the
protein and/or mRNA level are sensitive to gluco cor -
ticoid induced apoptosis (63), whereas those that fail
to autoinduce GR are resistant (64). Taken together,
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these data suggest that the GR expression level may
be an important determinant of the response of
malignant cells to glucocorticoids and that glucocor -
ticoid sensitivity may critically depend on the effect of
GR agonists on the number of intracellular GR
molecules (65).
Glucocorticoid receptor isoforms
A host of GR isoforms, all deriving from a single
GR gene, exhibit tissue-specific patterns of expres -
sion, as well as differences in subcellular localization
and transcriptional activity (66–68). It is deemed that
the repertoire of GR subtypes expressed by a
particular cell may contribute to the ability of the cell
to respond to glucocorticoids. Transcriptional, post-
transcriptional, and translational mechanisms are all
involved in controlling both the level of GR gene
expression and the generation of a number of specific
GR isoforms.
The GR gene has been mapped to chromosome
5 (5q31–32). The human GR cDNA was first cloned
in 1985 (69) and subsequently it was found that the
gene covers an 80 kb region and contains 9 exons
(70). Recent studies have identified 9 alternative
variants of exon 1 generated as a result of cell type-
specific alternative promoter usage (71), as well as
additional variability in exon 1 resulting from
alternative splicing (72). The 5’-untranslated region
occupies the whole exon 1 and a part of exon 2, so
that the heterogeneity in exon 1 does not affect the
sequence of the GR protein itself. However, the
existing cell type-specific promoter usage may serve
to regulate GR protein levels (71), alternative splicing
at other sites in the primary GR transcript (73),
and/or alternative translational initiation of mature
GR mRNA (74), all of which are important factors in
determining glucocorticoid sensitivity.
Alternative splicing of the GR precursor mRNA
gives rise to five GR protein subtypes that have been
termed GRa, GRb, GRg, GR-A, and GR-P (75).
Upregulation of some of these isoforms may
represent one of many mechanisms for modulating
cellular responsiveness to glucocorticoids. The
ubiquitously expressed GRa (777 amino acids) is the
classic, functionally active receptor and is generated
through splicing of exon 8 to the proximal end of
exon 9 (9a), whereas GRb (742 amino acids) is
produced through splicing of exon 8 to the distal end
of exon 9 (9b). Thus, GRa and GRb proteins share
identical N-termini encoded by exons 2–8 and are
distinguished only by their C-termini (69). GRa is
repressed by its ligand-binding domain (LBD)
occupying the C-terminal part of the molecule, so
that its nuclear import is allowed only upon ligand
binding. In the GRb the stretch of 50 C-terminal
amino acids is replaced by a unique 15-amino acid
tail that keeps the protein constitutively localized to
the nucleus. GRb is detected in most tissues and cell
lines, but is generally expressed at lower levels than
GRa (70, 76). It has been reported not to bind
glucocorticoid agonists and was originally thought to
control transcription only through a dominan t-ne -
gative effect on GRa-induced gene expression (77).
In support of a dominant-negative function for GRb,
resistance to glucocorticoid therapy in leukemia has
been associated with high cellular levels of GRb (78).
Recent studies, however, suggest that GRb may have
a previously unappreciated role in cell signaling and
the contribution of relative GRb levels in determining
cellular sensitivity to glucocorticoids in individuals
undergoing glucocorticoid therapy for malignancies
remains unclear (79). The GRg isoform contains a
three base insertion in the DBD between exons 3 and
4 that results in addition of arginine between the two
zinc fingers of the DBD (80). Since it exhibits
decreased transcriptional activity when compared to
GRa, its elevated levels are associated with
glucocorticoid resistance in childhood leukemia (81).
The GR-A and GR-P splice variants lack portions of
the LBD and studies from a number of laboratories
have revealed a correlation between elevated levels of
these isoforms and glucocorticoid resistance in
myeloma and leukemia (82). However, more recent
data suggest that GR-P may act in a cell type-specific
manner to enhance glucocorticoid responsiveness
(83).
Yet another mechanism for generating diversity
in GR protein expression is alternative translation
initiation. Yudt and Cidlowski (68) have shown that
this mechanism gives rise to tissue-specific GRa and
GRb isoforms expression patterns. All translational
isoforms exhibit a similar affinity for glucocorticoids
and most of them undergo hormone-induced nuclear
localization, followed by GRE binding and
transcriptional regulation (66). However, they differ
by their transcriptional activity in reporter assays, so
that the specific intracellular pool of GRa subtypes
may determine cellular sensitivity to glucocorticoids.
Besides, microarray analysis revealed that GRa
translational isoforms regulate unique, subtype-
specific genes (66).
Mutations in the glucocorticoid receptor gene
Mutations in the GR gene are considered the
primary cause of an inherited form of generalized
glucocorticoid resistance and also of in vitro acqui -
sition of glucocorticoid resistance in various malig -
nant cell lines. Hillmann et al. were the first to disco -
ver a transactivation-deficient GR mutant (L753F) in
cells from an individual with glucocor ticoid-resistant
ALL (84). Subsequently, an LBD-deficient GR mutant
(702) in cells from another individual with
glucocor ticoid-resistant ALL at relapse was identified
(85). The two cases described above are the only
known exam ples of resistance to glucocorticoid
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therapy in ma lig nancy attributable to acquired GR
mutations in vivo. However, in light of the low
sensitivity of conven tional assays for identification of
GR gene mutations in heterogeneous cell popu -
lations, it is likely that the acquisition of GR mutations
in vivo is underestimated.
Glucocorticoid receptor gene polymorphisms
Several polymorphisms in the GR gene have
been associated with variations in GR function. Thus,
the ER22/23EK GR polymorphism within the N-
terminal domain of the receptor has been associated
with decreased GR transcriptional activity in reporter
assays and with decreased expression of target genes
when compared to wild type GR (86, 87). Upon
further analysis, it was discovered that this
polymorphism facilitated the expression of GRa-A,
but had no effect on the expression of the GRb-B
translational isoforms (88). Since GRa-A is
transcriptionally less active than GRb-B (68), it can be
proposed that ER22/23EK may correlate with
glucocorticoid insensitivity (88). Similarly, the GRb
polymorphism A3669G located in the 3’untranslated
region of the gene results in enhanced expression of
the dominant-negative GRb protein and is associated
with favorable metabolic parameters (89). These data
imply that both ER22/23EK and A3669G carriers
have more a favorable metabolic profile due to
relative insensitivity to endogenous glucocorticoids. In
contrast to the polymorphisms described above, other
two polymorphisms in the GR gene, Bcl I – located in
intron 2 and N363S – located in the N-terminal
domain, have been associated with generalized
increase in glucocorticoid sensitivity (87, 90) and
metabolic disorders (91). Interestingly, microarray
analysis revealed a unique, 23 poly mor phism-specific
pattern of gene regulation for N363S when com -
pared to GRa wild type (92). Moreover, some reports
suggest that N363S is not only associated with
glucocorticoid hypersensitivity, but also with de cr e -
ased bone mineral density (93). Further analyses have
led to the proposal that polymorphisms in the GR
gene may be utilized as an indicator of disease, a
predictor of adverse reactions and a prognostic factor
in glucocorticoid-managed proliferative disorders
(65).
Glucocorticoid receptor heterocomplex
Since the integrity of the mature GR hetero -
complex is required for optimal ligand-binding and
subsequent activation of the transcriptional response,
abnormalities in the chaperones and co-chaperones
that make up the GR heterocomplex may contribute
to decreased glucocorticoid responsiveness. The
alterations in Hsp90 and Hsp70 were shown to be
associated with decreased cellular sensitivity to
glucocorticoids. For example, an aberrant form of
Hsp90 and low Hsp70 levels were identified in two
out of nine glucocorticoid-resistant human leukemic
cell lines (94). In addition, altered levels of Hsp90
were found in peripheral lymphocytes from indivi -
duals with steroid-resistant forms of asthma (95),
multiple sclerosis (96) and idiopathic nephritic syn -
dro me (97).
Furthermore, the relative levels of FKBP51 and
FKBP52 immunophilins have also been regarded as
important determinants of cellular sensitivity to
glucocorticoids in various systems. For example, high
levels of FKBP51 and low levels of FKBP52 were
associated with glucocorticoid resistance in cell lines
and tissues from several genera of New World
primates (98), while FKBP51 overexpression inhibited
hormone induced GR transactivation in mammalian
cells (99). As mutated versions of chaperones and co-
chaperones could alter signaling through the mature
GR heterocomplex, potentially leading to decreased
cellular sensitivity to glucocorticoid-induced cell
death, the role of these proteins in glucocorticoid-
resistant malignancy has been a matter of consi -
deration (100).
Modulation of glucocorticoid receptor
expression and function in disease
A part of the research conducted in our
laboratory is concerned with the modulation of
human GR structure, function and expression in
various diseases, the etiology and pathophysiology of
which are closely associated with the glucocorticoid
hormones action. These studies are performed on the
GR from isolated peripheral blood mononuclear cells
(PBMCs), as readily accessible human cells that
express high levels of GR and, being a part of the
immune system, represent an excellent model for
investigations of the molecular basis of antiinflam -
matory and immunosuppressive actions of the
glucocorticoid hormones.
Moreover, there is an increasing body of
evidence pointing to similarities between the receptor
expression and mechanisms of action in the cells of
the nervous system (e.g. neurons and glia) and
lymphocytes, as well as to a central role of lympho -
cytes in integrating the CNS and immunological
functions.
Considering the evidence along these lines
Gladkevich et al. (101) provided strong arguments to
support the exploiting of blood lymphocytes as a
convenient neural probe and a possible genetic probe
in studies of psychiatric disorders.
In this section we present our experimental data
on functional modulation and alterations in the
expres sion of GR in PBMCs from patients with asthma
as a typical inflammatory disease, polycystic ovary
synd ro me (PCOS) as an endocrinopathy bearing
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charac teristics of a metabolic disorder and posttra -
umatic stress disorder (PTSD) as a psychiatric disor -
der asso ciated with disturbances in the HPA axis
regulation.
Asthma
Asthma is the most common chronic disease
among children and adolescents. The pathogenesis
and pathophysiology of this disease are known to be
associated with alterations of GR function and also
with persistent pulmonary inflammation, the
important mediators of which are reactive oxygen and
nitrogen species. To improve symptoms and bronchial
hyperresponsiveness, and to limit the progressive
decline in lung function, glucocorticoids are used as
primary therapeutic agents, although the role of
glucocorticoid hormones and their receptor in the
pathophysiology and development of the disease is
poorly understood. In our laboratory the GR
hormone-binding parameters and the level of the
receptor expression in PBMCs from stable asthmatic
adolescents with different degrees of disease severity
have been investigated. It was found that adolescent
patients suffering from moderate asthma display
altered GR functional characteristics in comparison to
healthy subjects and mild asthmatics. Specifically,
they present a higher number of GR per cell (Bmax)
and lower affinity of the receptor for the hormone
(1/KD). However, the GR protein level was found to
be similar in PBMCs from the three groups of subjects
(102). Subsequently we tested a hypothesis that GR
functional alterations in asthma result from the action
of oxidants. To that end we conducted a series of ex
vivo treatments of PBMCs from healthy donors with
various oxidizing agents and compared the resulting
GR modifications with those previously noticed in
asthmatic patients. The results showed that treatment
of PBMCs by hydrogen peroxide (H2O2) provoked an
increase in the level of GR protein, accompanied by a
rise in the Bmax and a decline of 1/KD. The H2O2-
induced changes, including characteristic GR
isoproteins expression pattern, were found to be very
similar to the GR changes previously observed in
PBMCs of moderate asthmatic patients, but not in
mild asthmatics and healthy subjects. Treatment with
other oxidants applied herein produced distinct
effects, or exerted no influence on GR. Therefore, this
study provided preliminary data suggesting that func -
tional alterations of the GR associated with mo derate
asthma may be mediated by redox mechanisms that
are based on oxidative and regulatory actions of
H2O2 (103).
Polycystic ovary syndrome
Polycystic ovary syndrome (PCOS) is a common
endocrinopathy of the reproductive-aged women that
is characterized by hyperandrogenic features, with an
estimated prevalence of 5–10% (104). Apart from
ovaries as the main source of androgens, excess adre -
nal androgens, as well as adrenocortical dysfunction
were observed in women with PCOS (105). At pre -
sent, PCOS is considered a metabolic disorder with a
number of obesity-related risk factors for cardio -
vascular disease, specifically: insulin resistance, type
2 diabetes, and proatherogenic lipid profile (106).
Metabolic derangements presented by central obesity,
hyperlipidemia and insulin resistance are principally
linked to the glucocorticoid excess (107), which
might be explained by obesity-related increased tissue
sensitivity to glucocorticoids (108), or decreased
sensitivity to hypercholesterolemia (109). Therefore,
we focused our study to analyze the possible causative
relationship between the functional properties of the
GR in PBMCs from women with PCOS and their
clinical characteristics including biochemical blood
para meters. The examined GR functional characte -
ristics, Bmax and 1/KD, as well as the Bmax/KD ratio
called GR potency, were related to the anthropo -
metric data, basal biochemical characteristics, insulin
sensitivity indices and hormonal profile of the
subjects. We observed a strong association between
Bmax and KD, and also between GR potency and age
of the PCOS women. The multiple regression
analyses performed on the PCOS group showed that
independent predictors of KD were body mass index,
and plasma levels of total cholesterol and de hydro -
epiandro sterone-sulphate (DHEA-S), while the inde -
pen dent predictors for the GR potency were age,
body mass index, DHEA-S and basal cortisol concen -
tration (Macut et al., 2009, submitted for
publication). These findings should be elucidated in
further studies analyzing the possible role of the GR in
the pathogenesis of PCOS and metabolic consequ -
ences of the syndrome. 
Posttraumatic stress disorder
Posttraumatic stress disorder (PTSD) is a chronic
psychiatric disorder that can occur in subjects who
have been exposed to or have witnessed a traumatic
experience of an extreme nature. PTSD is typically
accompanied by acute and chronic alterations in the
stress response, i.e. with a deregulation of the HPA
axis. In addition, previous studies have suggested
altered GR expression and function in PBMC patients,
but have yielded conflicting results, presumably
because of not differentiating between the effects of
PTSD pathology and war-related trauma. The aim of
our study was to examine the GR expression and
functional properties in PBMCs of Balkan war
veterans with and without PTSD, in order to
discriminate between PTSD- and war trauma-related
alterations. GR hormone-binding parameters, Bmax
and equilibrium dissociation constant (KD), were
determined by saturation analysis in the PBMCs of
war veterans with current or lifetime PTSD and
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without PTSD, and of healthy male volunteers.
Functional status of the receptor was assessed by
measuring dexamethasone-induced inhibition of
lysozyme synthesis. The levels of GR, mineralocor -
ticoid recep tor (MR) and heat shock proteins (Hsp90
and Hsp70) were evaluated by quantitative immuno -
blotting. An increase of Bmax in the PBMCs of war
veterans without PTSD vs. healthy controls and a rise
of GR potency (Bmax/KD ratio) in patients with lifetime
PTSD vs. those with the current disorder were
noticed. Current PTSD coincided with disturbance of
the correlation between Bmax and KD that normally
exists in PBMCs of healthy subjects (110). Between-
group differences in sensitivity of lymphocytes to
dexamethasone were marginally significant, while
those in the levels of GR, MR, Hsp90 and Hsp70
were not found. The results suggest that current
PTSD may be associated with impairment of the
compensation between GR number and its affinity for
the hormone, resilience to PTSD with efficient
regulation of the receptor’s hormone-binding capa -
city and remission of the disorder with its elevated
binding potency (Mati} et al., in preparation). New
techniques such as cDNA microarray and proteomics
may give clues to define molecular abnormalities in
psychiatric disorders and could eventually reveal
infor mation for diagnostic and treatment purposes. 
Perspectives
Although many of the physiological effects of
glucocorticoid hormones are well recognized, the
underlying genomic mechanisms are only starting to
be elucidated. During the last decade the field of
genomics achieved a revolutionary advancement
through development of a powerful large-scale gene
expression profiling technology, including DNA
microarrays, serial analysis of gene expression and
proteomics, which allow rapid quantitative analysis of
entire transcriptomes and proteomes. Understanding
the molecular mechanisms by which glucocorticoid
hormones exert their diverse metabolic and physio -
logical effects requires identifying the direct target
genes whose expression levels are modulated by the
glucocorticoid signaling pathway. Moreover, a
complete understanding of the glucocorticoid action
also requires the transcription factors that may
interact with the GR, and the loci where these
interactions occur. The genome-wide in silico search
for GRE sequences in combination with genome-wide
location analysis, which may yield the set of
promoters bound by the GR, and profiling of the
expression levels of thousands of genes, which may
identify genes that are functionally dependent upon
the GR, enables the researchers to identify the set of
glucocorticoid-regulated genes and also to propose
interactions between the GR and other transcription
factors at specific target genes. Such novel
approaches may generate gene regulatory networks
and promise to provide explanations of transcriptional
regulation of candidate genes that underlie the
glucocorticoid-mediated effects in different cell types,
under diverse conditions and throughout time (111).
Although linking physiology and genomics appears to
be a complicated task, owing to a rapid progress of
the large-scale gene expression profiling technologies
and computational biology, our understanding of the
complexity of glucocorticoid signaling has rapidly
increased during the last decade. This progress has
provided significant insight into the key role of these
hormones not only in the maintenance of homeo -
stasis, but also in the pathogenesis of disease. It has
also made a major contribution to our understanding
of the molecular mechanisms underlying both
beneficial and adverse effects of the steroids used as
drugs, and provided the basis for future development
of more targetted glucocorticoid therapies.
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